Analyst: Obesity competition is good for Novo
According to analyst Søren Løntoft Hansen, Sydbank, it could turn out to be a positive development for Novo Nordisk and its Victoza business if US company Orexigen wins approval for its obesity drug.
by Stefan Singh Kailay
Last week’s announcement that US company Orexigen had submitted a registration application to the EMA for its obesity drug Contrave could turn out to be good news for Novo Nordisk and the Danish company’s own opportunities on the obesity market with diabetes drug Victoza – even if the Americans are the first to enter the market.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Novo in new Danish collaboration
For abonnenter
Novo: Our focus is on drugs and pen systems
For abonnenter
Novo Nordisk presents positive Tresiba data
For abonnenter
